Pharmacokinetic monitoring of mycophenolate mofetil in kidney transplanted patients

Farmaco

Volumn 55, Issue 4, 2000, Pages 270-275

  Brusa, Paola ^a   Ceruti, Maurizio ^a   Casullo, Rosella ^a   Dosio, Franco ^a   Squiccimarro, Giuseppe ^b   Paolo Segoloni, Giuseppe ^b   Cattel, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Divisione di Nefrologia e Dialisi   (Italy)

Author keywords

Immunosuppressant; Mycophenolate mofetil; Pharmacokinetics

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE;

ADMINISTRATION, ORAL; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PRODRUGS; TIME FACTORS;

EID: 0033849019     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(00)00039-2     Document Type: Article

References (16)

1. Lipsky J.J. Mycophenolate mofetil. The Lancet. 348:1996;1357-1359.
2. Bullingham R., Monroe S., Nicholls A., Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J. Clin. Pharmacol. 36:1996;315-324.
3. Fulton B., Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 51:1996;278-298.
4. Young C.J., Sollinger H.W. RS-61443: a new immunosuppressive agent. Transplant. Proc. 26:1994;3144-3146.
5. Lee H.-J., Pawlak K., Nguyen B.T., Robins R.K., Sad'ee W. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res. 45:1985;5512-5520.
6. Morris R.E., Wang J. Comparison of the immunosuppressive effects of mycophenolic acid in the morpholinoethyl ester of mycophenolic acid (RS-61443) in recipients of heart allografts. Transplant. Proc. 23:1991;493-496.
7. Morris R.E., Hoyt E.G., Murphy M.P., Eugui E.M., Allison A.C. Mycophenolic acid morpholinoester (RS-61443) is a new immunosuppressant that prevents an halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant. Proc. 22:1990;1659-1662.
8. Deierhoi M.H., Sollinger H.W., Diethelm A.G., Belzer F.O., Kauffman R.S. One-year follow-up results of a phase I trial in mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant. Proc. 25:1993;693-694.
9. Sollinger H.W., Belzer F.O., Deierhoi M.H., Diethelm A.G., Gonwa T.A., Kauffman R.S., Klintmalm G.B., McDiarmid S.V., Roberts J., Rosenthal J.T., Tomlanovich S.J. RS-61443: rescue therapy in refractory kidney transplant rejection. Transplant. Proc. 25:1993;698-699.
10. Behrend M. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Clin. Nephrol. 45:1996;336-341.
11. Bullingham R., Nicholls A., Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant. Proc. 28:1996;925-929.
12. Mycophenolate Mofetil Prescribing Information. 1995;Hoffmann-La Roche Inc, Nutley, NJ.
13. Product Information CellCept. 1996.
14. Tsina I., Chu F., Hama K. Manual and automated (robotic) high-performance liquid chromatography methods for determination of mycophenolic acid and its glucuronide conjugate in human plasma. J. Chromatogr. B. 675:1996;119-129.
15. Behrend M., Lueck R., Pichlmayr R. Mycophenolic acid and mycophenolic acid glucuronide trough levels after renal transplantation. Transplant. Proc. 29:1997;2936-2938.
16. B. Krumme, Pharmacokinetics monitoring of mycophenolic acid (MPA) in the early period after renal transplantation. Prog. Transplant. Med. (1997) October 22-24, Nice, France.